Epidiolex became the first CBD medication approved by a national regulator for severe childhood epilepsy
Phase III RCTs led to FDA approval of Epidiolex (pharmaceutical CBD) for Dravet and Lennox-Gastaut syndromes, marking the first cannabis-derived medication approved by a national regulatory agency, though its use for other epilepsy syndromes remains undetermined.
Quick Facts
What This Study Found
Epidiolex (>99% CBD, <0.10% THC) received FDA approval for Dravet and Lennox-Gastaut syndromes and EMA approval for Lennox-Gastaut syndrome, based on Phase III RCTs and open-label trials demonstrating efficacy and safety. CBD mechanism of action remains unknown and does not appear to work through cannabinoid receptors.
Key Numbers
Epidiolex: >99% CBD, <0.10% THC. FDA approved for Dravet and Lennox-Gastaut syndromes. EMA approved for Lennox-Gastaut syndrome. Based on Phase III RCTs and open-label trial data.
How They Did This
Review of the history, pharmacology, and clinical trial data supporting CBD approval for epilepsy, including Phase III RCTs and prospective open-label trials.
Why This Research Matters
Epidiolex approval represents a watershed moment: the first time a cannabis-derived compound passed the full regulatory approval process. It validates the therapeutic potential of cannabinoids while setting a standard for evidence-based cannabis medicine.
The Bigger Picture
The Epidiolex approval demonstrates that cannabis-derived compounds can meet the same rigorous standards as any other medication. It also highlights how far the field needs to go, as the complete spectrum of cannabis-derived products and their use for other conditions remains to be determined.
What This Study Doesn't Tell Us
Approval is limited to two rare epilepsy syndromes. CBD mechanism of action is still unknown. The review does not address effectiveness of non-pharmaceutical cannabis products for epilepsy. Long-term safety data is still accumulating.
Questions This Raises
- ?Will CBD receive approval for other epilepsy types?
- ?What is its anti-seizure mechanism if not through cannabinoid receptors?
- ?How do non-pharmaceutical cannabis products compare in efficacy and safety?
Trust & Context
- Key Stat:
- First FDA-approved CBD drug
- Evidence Grade:
- Rated strong because the approval was based on Phase III randomized controlled trials meeting full regulatory standards.
- Study Age:
- Published in 2019, shortly after FDA approval. Additional indications and post-market data have continued to accumulate.
- Original Title:
- Cannabinoid therapy in epilepsy.
- Published In:
- Current opinion in neurology, 32(2), 220-226 (2019)
- Authors:
- Billakota, Santoshi, Devinsky, Orrin(9), Marsh, Eric(3)
- Database ID:
- RTHC-01943
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is Epidiolex?
A pharmaceutical-grade CBD product (>99% CBD, <0.10% THC) that is the first cannabis-derived medication approved by the FDA, for treating seizures in Dravet and Lennox-Gastaut syndromes.
Does CBD work for all types of epilepsy?
Approval is currently limited to two specific severe childhood epilepsy syndromes. Whether CBD is effective for other epilepsy types remains to be determined through further research.
How does CBD stop seizures?
The anti-seizure mechanism of CBD is unknown. Unlike THC, CBD does not appear to work through cannabinoid receptors, and its exact target in the brain has not been identified.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01943APA
Billakota, Santoshi; Devinsky, Orrin; Marsh, Eric. (2019). Cannabinoid therapy in epilepsy.. Current opinion in neurology, 32(2), 220-226. https://doi.org/10.1097/WCO.0000000000000660
MLA
Billakota, Santoshi, et al. "Cannabinoid therapy in epilepsy.." Current opinion in neurology, 2019. https://doi.org/10.1097/WCO.0000000000000660
RethinkTHC
RethinkTHC Research Database. "Cannabinoid therapy in epilepsy." RTHC-01943. Retrieved from https://rethinkthc.com/research/billakota-2019-cannabinoid-therapy-in-epilepsy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.